Xbrane Acquires Rights to Protein Production System From Vaxiion
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
The Swedish biotech company Xbrane Bioscience and the San Diego based biotech company Vaxiion Therapeutics, Inc. have announced that they have reached a licensing arrangement granting Xbrane Bioscience rights to Vaxiion’s proprietary protein production system – the Rhamex System™.
The agreement enables Xbrane Bioscience to distribute and sell the protein expression system for both research and commercial purposes in addition to utilizing the system for their in-house protein production services business.
“The pharma industry expresses a great need for efficient and cost-effective methods for production of proteins. Proteins are the basis in half of all new drugs and proteins are crucial tools in drug discovery. The problem is that some proteins are very difficult and expensive to produce. The Rhamex System™ is a bacterial-based protein production system that has the ability to express larger amounts of host-toxic and active proteins than many other systems. We think the Rhamex System™ may be able to solve many problems for the industry,” explains Jan-Willem de Gier, Ph.D., Chief Technical Officer at Xbrane Bioscience.
Protein expression in the Rhamex System™ is tightly regulated at the individual cell level via rhamnose induction and enables production of high yields of more bioactive and correctly folded proteins per production run. The mechanism of induction allows for slower, uniform production of proteins compared to the all-or-nothing induction mechanisms characteristic of other systems.
The Rhamex System™ commonly uses the gram-negative bacteria E. coli as production host cell but is amenable to use in other gram-negative hosts.
Xbrane Bioscience is a spin-off from the Centre for Biomembrane Research, at Stockholm University. The company develops and commercializes platforms for efficient and cost-effective production of proteins and vaccines.
The agreement enables Xbrane Bioscience to distribute and sell the protein expression system for both research and commercial purposes in addition to utilizing the system for their in-house protein production services business.
“The pharma industry expresses a great need for efficient and cost-effective methods for production of proteins. Proteins are the basis in half of all new drugs and proteins are crucial tools in drug discovery. The problem is that some proteins are very difficult and expensive to produce. The Rhamex System™ is a bacterial-based protein production system that has the ability to express larger amounts of host-toxic and active proteins than many other systems. We think the Rhamex System™ may be able to solve many problems for the industry,” explains Jan-Willem de Gier, Ph.D., Chief Technical Officer at Xbrane Bioscience.
Protein expression in the Rhamex System™ is tightly regulated at the individual cell level via rhamnose induction and enables production of high yields of more bioactive and correctly folded proteins per production run. The mechanism of induction allows for slower, uniform production of proteins compared to the all-or-nothing induction mechanisms characteristic of other systems.
The Rhamex System™ commonly uses the gram-negative bacteria E. coli as production host cell but is amenable to use in other gram-negative hosts.
Xbrane Bioscience is a spin-off from the Centre for Biomembrane Research, at Stockholm University. The company develops and commercializes platforms for efficient and cost-effective production of proteins and vaccines.
